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Prolactin (PRL) is a hormone principally secreted by lactotrophs of the anterior pituitary 
gland. Although the synthesis and exocytosis of this hormone are mainly under the 
regulation of hypothalamic dopamine (DA), the possibility that the anterior pituitary 
synthesizes this catecholamine remains unclear. In this study, our aim was to determine 
if the anterior pituitary produces DA from the precursor L-Dopa. To this purpose, we 
studied the expression of aromatic L-amino acid decarboxylase (AADC) enzyme and 
the transporter VMAT2 in the anterior pituitary, AtT20 and GH3 cells by 
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from L-Dopa and its release in vitro. Then, we explored the effects of L-Dopa in the 
secretion of PRL from anterior pituitary fragments. We observed that the anterior 
pituitary, AtT20 and GH3 cells express both AADC and VMAT2. Next, we detected an 
increase in DA content after anterior pituitary fragments were incubated with L-Dopa. 
Also, the presence of L-Dopa increased DA levels in incubation media and reduced 
PRL secretion. Likewise, the content of cellular DA increased after AtT20 cells were 
incubated with L-Dopa. In addition, L-Dopa reduced CRH-stimulated ACTH release 
from these cells after AADC activity was inhibited by NSD-1015. Moreover, DA 
formation from L-Dopa increased apoptosis and decreased proliferation. However, in 
the presence of NSD-1015, L-Dopa decreased apoptosis and increased proliferation 
rates. These results suggest that the anterior pituitary synthesizes DA from L-Dopa by 
AADC and this catecholamine can be released from this gland contributing to the 
control of PRL secretion. In addition, our results suggest that L-Dopa exerts direct 




Prolactin (PRL) is a polypeptide hormone predominantly secreted by lactotrophs of the 
anterior pituitary. Beyond reproduction and lactation, PRL is involved in a broad 
spectrum of functions, including metabolism control, behavior, immunoregulation, 
osmoregulation and neuroendocrine response to stress (1). It has been accepted that 
lactotrophs have high basal secretory activity and that the main control of PRL secretion 
is exerted by hypothalamic inhibition.. In fact, the lack of a specific endocrine gland as 
its target and the multiplicity of PRL actions result in the absence of a classical negative 
feedback control (2). 
A significant body of evidence shows that dopamine (DA) is the most important 
hypothalamic prolactin-inhibiting factor (3). This catecholamine exerts a direct effect on 
lactotrophs through binding to dopaminergic D2 receptor subtype expressed on their 
cell membrane. Activation of this receptor results in the suppression of PRL gene 
expression, inhibition of PRL exocytosis, reduction of lactotroph proliferation and 
induction of apoptosis (3-5).  
Due to the lack of a classical hormone-mediated negative feedback pathway, PRL itself 
provides the afferent signal necessary to promote such a regulatory mechanism in a 
process known as short-loop feedback. Through the expression of PRL receptors 
(PRLR) in dopaminergic neurons, PRL stimulates hypothalamic DA synthesis and 
increases the release of DA in the pituitary portal blood (6). Therefore, additional PRL 
secretion from lactotrophs is suppressed. In addition, we observed that PRL exerts 
control actions at pituitary level itself, increasing apoptosis and reducing proliferation of 
lactotrophs (7).  
Dopamine neurons that control PRL secretion are located in the hypothalamic arcuate 
and periventricular nuclei. These neurons are arranged into three sub-populations: the 
tuberoinfundibular (TIDA), tuberohypophyseal (THDA), and periventricular 
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nucleus and project to the median eminence, releasing DA into the pituitary long portal 
system. While THDA neurons project from the arcuate nucleus to the pituitary 
neurointermediate lobe PHDA neurons originate in the periventricular nucleus and end 
in the intermediate lobe. THDA and PHDA neurons transport DA to the anterior 
pituitary through short portal vessels from the neurointermediate lobe (6). 
Dopamine is synthesized from the amino acid tyrosine by two enzymes that act 
sequentially. Tyrosine hydroxylase (TH), the rate-limiting enzyme, converts this amino 
acid to L-Dopa. Then, L-Dopa is decarboxylated to DA by aromatic L-amino acid 
decarboxylase (AADC). The synthesized DA is stored at high concentration inside 
secretory vesicles. Such structures prevent DA molecules from enzymatic degradation, 
minimize its diffusion through the cytoplasmic membrane, regulate its secretion by 
exocytosis, and enable its rapid cellular replenishment. Dopamine is translocated from 
the cytoplasm into the secretory vesicles by the vesicular monoamine transporter 
(VMAT). Transport of DA to vesicles is mediated by an electrochemical gradient 
generated by an ATP-dependent H+ pump. Two isoforms of this vesicular transporter 
coexists: VMAT1 and VMAT2. They arise from distinct but related genes that encode 
proteins of ~520 residues (8). VMAT1 is present in developing neurons, peripheral 
tissues, and in some endocrine cells. VMAT2 is expressed in all major monoaminergic 
neurons throughout the brain (3). 
Dopamine can also undergo oxidative deamination by monoamine oxidase (MAO) to 
produce dihydroxyphenylacetic acid (DOPAC) and reactive oxygen species (ROS) (9). 
In addition to dopaminergic neurons expressing TH and AADC, there are 
monoenzimatic ones that express only one of the enzymes of DA synthesis. In fact, the 
arcuate nucleus of the hypothalamus is rich in monoenzymatic neurons. Numerous 
monoenzymatic TH axons terminate in the median eminence, close to the primary 
capillary of the hypophyseal portal system (10). These observations suggest a pathway 
for the delivery of L-Dopa towards the hypophyseal portal circulation. In fact, while it 
was reported in female rats that the portal plasma DA concentration is around 6 ng/ml 
(11), Telford et al. (1992) have observed that the L-Dopa concentration is around 40 
ng/ml in NSD 1015-treated animals (12).  
The synthesis of DA by anterior pituitary cells has long been in debate. Previous 
research described that in some physiological or experimental conditions the anterior 
pituitary expresses TH (13) and synthesizes DA (14). However, in other studies TH 
activity in the anterior pituitary was not detected (12, 15). In fact, Schussler et al (1995) 
reported that TH primary transcript suffers alternative splicing in the anterior pituitary, 
suggesting that this gland produces TH proteins with no enzymatic activity (16).  
On the other hand, the findings about AADC activity in the anterior pituitary are 
contradictory (17, 18). The expression of TH in the rat anterior pituitary by an 
adenoviral vector reduces the gland hyperplasia and circulating PRL levels induced by 
chronic estradiol treatment. These observations suggest that DA is synthesized in the 
anterior pituitary gland by TH and AADC enzymes, inhibiting lactotroph growth and 
PRL secretion (19). 
In view of this background, we explored the expression and activity of AADC in the 
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explored the expression of the vesicular monoamine transporter VMAT2 in cells of the 
anterior pituitary. We observed that DA is synthesized in this gland from L-Dopa by 
AADC. Moreover, this DA can be released contributing to the control of PRL secretion. 
In addition, L-Dopa could modify anterior pituitary cell renewal. 
  
 
Materials and Methods 
Drugs  
Dulbecco’s modified Eagle’s medium (DMEM), 3,4-dihydroxy-L-phenylalanine (L-
Dopa), 3-hydroxybenzylhydrazine dihydrochloride (NSD-1015), pargyline 
hydrochloride, 5-Bromo-2′-deoxyuridine (BrdU) were purchased from Sigma-Aldrich 
(Missouri, USA). Cell culture supplements, 0.05% trypsin-EDTA and anti-guinea pig 
Alexa 555-conjugated antibody were obtained from Invitrogen (California, USA). Fetal 
calf serum (FCS) and horse serum were provided by Natocor (Córdoba, Argentina). All 
terminal deoxynucleotidyl transferase-mediated dUTP nick end labelling (TUNEL) 
reagents were acquired from Roche Molecular Biochemicals (Mannheim, Germany). 
The antibodies against anterior pituitary hormones were obtained from Dr. Parlow, 
National Hormone and Peptide Program (California, USA). Rabbit polyclonal anti-
AADC (Cat# AB1569), horseradish peroxidase (HRP) conjugated anti-rabbit (Cat# 
AP132P) and anti-mouse (Cat# AP130P) antibodies were bought from Millipore 
(California, USA). The specificity of anti-AADC antibody was previously established 
in rat (20) and mouse (21). Mouse monoclonal anti-vesicular monoamine transporter 2 
(VMAT2) was purchased from Santa Cruz Biotechnology (Cat# Sc-374079, Texas, 
USA). Anti-rabbit (Cat# FI-1000) and anti-mouse (Cat# FI-2001) FITC-conjugated 
secondary antibodies were acquired from Vector Laboratories (California, USA). The 
origin of other materials is indicated below. 
 
Animals 
All experimental procedures involving animals were approved by the Animal Care and 
Use Committee (CICUAL) of the School of Medicine, University of Buenos Aires 
(approval ID: Res. (CD) Nº 2369/2017). Adult male Wistar rats (300-350 g) were 
housed in groups of five animals per cage in a standard animal facility under controlled 
conditions of light (12:12 h light-dark cycles) and temperature (22-25 ºC). Rats were fed 
with balanced food pellets and tap water ad libitum. In all cases, animals were sacrificed 
by decapitation. Parietal bone was broken at the sagittal, coronal and lambdoid sutures 
and detached using a bone nipper. Brain was gently removed from the cranial cavity 
using a dental explorer exposing the pituitary gland. Posterior lobe together with the 
intermediate lobe were detached from the anterior lobe using a tissue forceps. Anterior 
pituitary was immediately extracted for use.    
 
Primary culture of anterior pituitary cells 
Pools of anterior pituitaries from 2 to 3 adult male Wistar rats were cut into small 
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DMEM-0.1% BSA (Sigma-Aldrich, Cat# A9418) containing 0.75% trypsin (Invitrogen 
Cat# 15090046), 10% FCS previously treated with 0.025 % dextran (Sigma-Aldrich 
Cat# D4751)-0.25 % charcoal (Sigma-Aldrich, Cat# C-5260) (FCS-DC) to remove 
steroids, and 45 U/µL deoxyribonuclease type I (Invitrogen, Cat# 18047-019). Cells 
were dispersed by extrusion through a Pasteur pipette in Krebs buffer Ca2+/Mg2+ free. 
Viability was assessed by trypan blue (Invitrogen, Cat# 15250061) exclusion. Dispersed 
cells were resuspended in DMEM – 10% FCS-DC and seeded on cover slides in 24-
wells tissue culture plates (2x105 cells/mL/well). Cultures were kept at 37 °C in a 
humidified atmosphere containing 5% carbon dioxide. After 24 h, cells were fixed in 
4% paraformaldehyde (PFA) and processed for immunofluorescence. 
 
Cell lines culture 
AtT20: This mouse ACTH-secreting pituitary adenoma cell line was chosen to carry out 
our research because they are of pituitary origin and can modulate the release of ACTH 
upon stimulation with CRH. AtT20 cells are widely used for assessing the effects of 
different stimulus on cell renewal, viability and ACTH secretion (22-28). These cells 
lack functional D2 receptors (29, 30). The cells were cultured in 75 cm2 tissue flasks 
without additional surface treatment, containing DMEM medium supplemented with 2 
mM L-glutamine, 0.1 mg/mL Gentamicin, and 10% FCS-DC.  
GH3: This somatolactotroph cell line is derived from a pituitary tumor of a female rat. 
Although these cells lack functional D2 receptor (31), they are often used in studies on 
rat pituitary cell function as it has been reported that these cells secrete PRL (32). The 
cells were cultured in 100 mm diameter Petri’s dishes without additional surface 
treatment, containing DMEM medium supplemented with 20 μL/mL MEM amino 
acids, 2 mM L-glutamine, 0.1 mg/mL Gentamicin, and 10% FCS-DC. 
PC12: We selected this rat pheochromocytoma cell line as a positive control for our 
experiments based on its dopaminergic properties which resemble DA neurons (33, 34). 
Cells were undifferentiated since enzyme expression and DA content are higher than 
NGF-treated cells (34). PC12 cells were cultured in 100 mm diameter Petri’s dishes 
without additional surface treatment, containing DMEM medium supplemented with 0.1 
mg/mL Gentamicin, 10% FCS-DC, and 5% horse serum.  
All cell lines were cultured in monolayer to a confluence of 80%. Cells were replicated 
once every three days during the logarithmic phase of growth up to the 7th passage. 
Cultures were kept at 37 °C in a humidified atmosphere containing 5% carbon dioxide. 
 
Immunofluorescence 
In order to identify the populations of anterior pituitary cells expressing AADC or 
VMAT2, we performed double indirect immunofluorescence staining. Cover slides 
containing 4% PFA fixed cells from anterior pituitary cell primary culture were 
permeabilized with 10 mM sodium citrate buffer (pH 6.0) using a microwave oven at 
100 mm diameter Petri’s dishes with flat and standard-treated surface 350 watts 
(AADC) or 700 watts (VMAT2) for 5 min. AADC cover slides were additionally 
permeabilized with PBS-0.5% Triton X-100. Non-specific sites were blocked with 
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Triton for 1 h. After blockage, cells were incubated for 1 h with anti-ACTH (1/3000), 
anti-PRL (1/3000), anti-GH (1/1500), or anti-LH (1/500) antibodies. Cells were 
incubated overnight at 4ºC with an anti-AADC (1/25) or an anti-VAMT2 (1/20) 
antibody, washed and incubated with FITC-conjugated anti-rabbit (1/100), or anti-
mouse (1/100) and Alexa 555-conjugated anti-guinea pig antibodies (1/100) for 1 h. 
Non-specific control was either incubated with inactivated serum or the IgG subtype 
instead of primary antibody. Finally, cover slides were mounted with Vectashield 
containing 4’,6-diamidino-2-phenylindole (DAPI) for DNA staining (Vector 
Laboratories, CA, USA) and visualized in an Axio Scope A1 fluorescence light 
microscope (Carl Zeiss; Jena, Germany) coupled to a digital camera (DP73, Olympus; 
Tokyo, Japan). 
The expression of AADC and VMAT2 was also evaluated in AtT20 and GH3 cells. 
Cells were harvested with 0.05% trypsin-EDTA (2 min at 37 ºC) and seeded on cover 
slides in 24-well tissue culture plates (2x105 cells/ml/well). Cells were processed as 




Total proteins were extracted from anterior pituitary glands and striatum from adult 
male Wistar rats, AtT20, GH3, and PC12 cells with lysis buffer (pH 7.4) containing 10 
mM Tris, 150 mM NaCl, 2 mM EGTA, 1% Triton X-100, 2.5 mM NaF, 0.5 mM 
Na3VO4, and a protease inhibitor cocktail (1/100; Sigma, Cat# P8340). Following 
homogenization and centrifugation at 16,000 g for 40 min, the supernatant was used for 
the immunoblot assay. The protein content of each sample was determined by the 
Bradford protein assay (BioRad Laboratories; California, USA). Thirty µg of total 
proteins were size-fractionated in 12% SDS-polyacrylamide gel and electrotransferred 
(66 mA, overnight) to PVDF membranes (BioRad, Cat# 162-0177). Correct protein 
loading and transfer efficiency were assessed by membrane staining with red Ponceau. 
Then, blots were blocked for 2 h in 5% non-fat dry milk PBS 0.1% Tween 20 (PBST) 
and incubated overnight at 4ºC with anti-AADC (1/400), or anti-VMAT2 (1/100) 
antibodies in blocking buffer. After washing, membranes were incubated 1 h with HRP-
conjugated anti-rabbit or anti-mouse antibody (1/1000) in blocking buffer. 
Immunoreactivity was detected by enhanced chemiluminescence (Kalium technologies, 
Argentina) in a G Box Chemi HR16 imaging system (Syngene; Cambridge, UK). 
 
Determination of DA and DOPAC levels 
In anterior pituitary experiments, the concentration of tissue and secreted DA and 
DOPAC were determined by high-performance liquid chromatography (HPLC) using a 
Spectra System P2000 equipment coupled to an electrochemical detector (BAS CC-5). 
Tissue samples were lysed and deproteinized in 0.2 N HClO4. Homogenates and culture 
media samples were centrifuged at 11,500 g for 2 min. The supernatant (20 µL) was 
injected into a 3.9 x 15 cm Nova-Pak C18 (Waters; Massachusetts, USA) reverse phase 
column. The mobile phase used for the separation consisted of 0.076 M NaH2PO4.H2O, 
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electrode potential was fixed at 0.7 V and the detector sensitivity was set to 2 for better 
peak resolution on chromatograms. Peak heights were measured by Peak Simple 
Chromatography Data System (Model 302 Six Channel 181 USB). Values were 
quantified based on standard curves using the same software. Dopamine and DOPAC 
contents per sample were expressed as pmol/mg of tissue. Assay sensitivities were 
0.122 pmol for DA and 0.883 pmol for DOPAC.    
The intracellular content of DA and DOPAC in AtT20 and GH3 cells was measured by 
HPLC as described above. Cells were seeded on 24-wells tissue culture plates (3x105 
cells/ml/well) and kept in culture for 48 h. Afterwards, cells were incubated with or 
without an AADC inhibitor (NSD-1015, 10 µM) or a MAO inhibitor (pargyline, 10 
µM) for 30 min. Then, L-Dopa (1 or 10 µM) was added for further 2 h. DA and 
DOPAC content per sample was normalized to total protein content (pmol/µg of 
protein). 
 
Prolactin and DA release experiments 
Anterior pituitaries from adult male rats were cut into two halves and stabilized for 30 
min in DMEM containing 0.1% BSA and 500 µM ascorbic acid at 37 ºC. After this 
period, the fragments were treated with or without L-DOPA (10 µM, 2 h). Dopamine 
and PRL release was measured in conditioned media. Dopamine and DOPAC content 
was evaluated by HPLC as described above. The levels of PRL in each sample were 
determined by an ultrasensitive ELISA developed by Guillou et al. (35). PRL content 
per sample was expressed as ng/mg tissue. 
 
ACTH release experiments 
AtT20 cells were seeded on 24-well tissue culture plates (2.5x105 cells/ml/well) and 
kept in culture for 48 h. After this period, cells were preincubated in the presence or 
absence of NSD-1015 (1 µM) for 30 min and, then, treated with or without L-Dopa (1 
µM, 3 h). All groups were incubated either under basal or CRH-stimulated (100 nM, 3 
h) (Bachem, California, USA) conditions. Next, media were collected and centrifuged. 
ACTH media content was assayed using a rat/mouse EIA kit (EK-001-21; Phoenix 
Pharmaceuticals Inc., California, USA) following the manufacturer’s instructions. 
ACTH content per sample was expressed as ng/mL. 
 
Apoptosis and proliferation experiments 
AtT20 cells were seeded on cover slides in 24-wells tissue culture plates (105 
cells/ml/well) for TUNEL or BrdU incorporation assays and kept in culture for 48 h. 
Later, cells were incubated with or without L-Dopa (1 µM; 8 h) in the presence or 
absence of NSD-1015 (1 µM) or MAO inhibitor pargyline (10 µM). Inhibitors were 
added 30 min before L-Dopa. For the proliferation assay, BrdU (200 µM, 8 h) was 
added to the culture media. After incubation periods, cells were fixed as previously 
described for immunofluorescence. 
For the BrdU incorporation assay, cells were permeabilized with 10 mM sodium citrate 
buffer (pH 6.0) using a microwave oven at 350 watts for 5 min (90°C). Next, cover 
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37 °C. Then, cells were blocked with 10% horse serum in PBS-0.2% Triton for 1 h and 
incubated overnight at 4 ºC with an anti-BrdU antibody (1/200, BD Bioscience Cat# 
555627; New Jersey, USA). Cells were washed and incubated with a FITC-conjugated 
anti-mouse antibody (1/100). Cover slides were mounted with Vectashield containing 
DAPI and visualized in a fluorescent light microscope. Non-specific control cover 
slides were incubated without BrdU. The percentage of proliferative cells was 
calculated as [BrdU+ cells/total cells] x 100. 
For the TUNEL assay, after permeabilization, DNA strand breaks were labelled with 
digoxigenin-dUTP (1/250) using terminal deoxynucleotidyl transferase (25 U/µL). After 
incubation with 10% sheep serum (Sigma) in PBS-2% BSA for 1 h, cells were 
incubated with a FITC-conjugated anti-digoxigenin antibody (1/10) for 1 h to detect 
incorporation of nucleotides into the 3´-OH end of damaged DNA. Cover slides were 
mounted with Vectashield containing DAPI and visualized in a fluorescent light 
microscope. Non-specific control slides were incubated without terminal 
deoxynucleotidyl transferase. The percentage of apoptotic cells was calculated as 
[TUNEL+ cells/total cells] x 100.  
Cells were counted using the multi-point option of ImageJ software (1.50e, Wayne 
Rasband, National Institutes of Health, USA). 
 
Statistical analysis  
GraphPad Prism version 6.00 for Windows (GraphPad Software, California, USA) was 
used for statistical data analysis. 
DA and DOPAC content experiments: All data are presented as mean ± SEM. Statistical 
analysis was performed using two-tailed unpaired t-test or one way ANOVA followed 
by Tukey’s multiple comparisons test. Differences were considered significant if 
p<0.05. 
PRL release experiments: Results are shown as mean ± SEM. Statistical analysis was 
performed using a two-tailed unpaired t-test. Differences were considered significant if 
p<0.05. 
ACTH release experiments: Results are displayed as mean ± SEM. Two-way ANOVA 
followed by Newman-Keuls’ multiple comparisons test was used to analyze the data. 
Differences were considered significant if p<0.05. 
Apoptosis and proliferation experiments: Data are expressed as the percentage of BrdU 
or TUNEL-positive cells ± 95% confidence limits (CL) of the total number of cells 
(evaluated by DAPI nuclear staining) counted in each specific condition. Differences 





AADC and VMAT2 expression in the anterior pituitary gland 
In order to study whether the anterior pituitary can decarboxylate L-Dopa to DA, we 
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single band at 55 kDa corresponding to AADC (36). To determine the cell types within 
the anterior pituitary that express AADC, double immunofluorescence for this enzyme 
and four anterior pituitary hormones was performed. As shown in Figure 1B, AADC 
was localized in corticotrophs, lactotrophs, somatotrophs and gonadotrophs. 
We also studied the expression of VMAT2 in the anterior lobe to determine whether 
DA could be stored in this gland. By means of western blot, we showed VMAT2 
expression (single band at 63 kDa) in the anterior pituitary (Fig. 2A). 
Immunofluorescence revealed that the vesicular transporter is also expressed in all 
pituitary cell subpopulations studied (Fig. 2B). 
 
Dopamine synthesis by the anterior pituitary gland 
Since AADC is expressed in cells of the anterior lobe, we studied the activity of this 
enzyme in anterior pituitaries incubated with L-Dopa ex vivo. We observed that the 
content of DA (Fig. 3A) and DOPAC (Fig. 3B) increased in the presence of L-Dopa (10 
µM), indicating sequential AADC and MAO activities in this gland. 
The presence of VMAT2 in the anterior lobe suggests the existence of DA-containing 
vesicles. Thus, we evaluated whether DA could be secreted from the anterior pituitary. 
We observed that L-Dopa increased DA content in incubation media (Fig. 3C) 
indicating that DA synthesized from L-Dopa by AADC is released from anterior 
pituitary cells.  
In order to assess whether DA produced from L-Dopa regulates PRL secretion, we 
measured PRL content in culture media from tissues incubated with L-Dopa. The 
presence of L-Dopa decreased PRL concentration in the media (Fig. 3D), suggesting 
that the anterior pituitary could regulate PRL secretion through an auto/paracrine 
mechanism mediated by endogenously produced DA. 
 
Dopamine synthesis by anterior pituitary cell lines 
Next, we determined AADC and VMAT2 expression in GH3 and AtT20 cells by 
western blot and immunofluorescence. The PC12 cell line was used as a positive 
control. Both GH3 and AtT20 cells expressed AADC and VMAT2 (Fig. 4). 
To evaluate the activity of AADC in these cell lines, we determined the synthesis of DA 
from L-Dopa by HPLC. Although we did not detect AADC activity in GH3 cells (data 
not shown), AtT20 cells incubated with L-Dopa (1 and 10 µM) produced DA and 
DOPAC, an effect abolished by the AADC inhibitor NSD-1015 (10 µM) (Fig. 5A, B). 
Additionally, the presence of MAO inhibitor pargyline (10 µM) increased DA content 
in response to L-Dopa (10 µM) and prevented the production of DOPAC (Fig. 5C). 
These results indicate that AtT20 cells metabolize L-Dopa to DA by AADC and that 
DA is oxidized to DOPAC by MAO. 
 
Effects of L-Dopa on ACTH release from AtT20 cells 
Considering that AADC activity was detected in AtT20 cells, we studied whether the 
conversion of L-Dopa to DA or L-Dopa per se could alter ACTH secretion. AtT20 cells 
were incubated with L-Dopa (1µM) with or without NSD-1015 (1 µM). In the absence 
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ACTH secretion (Fig. 6A, B). However, the co-treatment with L-Dopa and NSD-1015 
reduced ACTH secretion under CRH-stimulated conditions (Fig. 6B). These data 
suggest that L Dopa per se could act on stimulated ACTH secretion, independently of 
its conversion to DA. 
 
Effects of L-Dopa on apoptosis and proliferation of AtT20 cells 
We then investigated the effects of the co-treatment with L-Dopa and NSD-1015 on cell 
renewal in the AtT20 cell line. These cells were incubated with L-Dopa (1µM) in the 
presence or absence of NSD-1015 (1µM). While L-Dopa increased the percentage of 
apoptotic cells, the presence of NSD-1015 and L-Dopa induced a reduction in apoptotic 
cell number (Fig. 7A). On the contrary, L-Dopa reduced the percentage of proliferative 
AtT20 cells but, when its conversion to DA was inhibited by NSD-1015, L-Dopa 
enhanced their proliferation rate (Fig. 7B). NSD-1015 per se did not affect apoptosis or 
proliferation (Fig. 7A, B). Thus, DA synthesized from L-Dopa exerts a proapoptotic and 
antiproliferative action. In contrast, L-Dopa per se induces antiapoptotic and 
proliferative effects in AtT20 cells. 
 
Effects of MAO inhibition on apoptosis and proliferation of AtT20 cells 
Dopamine can trigger apoptosis in the anterior pituitary through D2R-dependent or -
independent mechanisms (4, 5, 37). Previous studies reported the absence of D2R 
expression in AtT20 cells (30). Therefore, the observed effects of DA on proliferation 
and apoptosis in these cells may result from D2R independent signaling. Hence, we 
hypothesized that the oxidation of DA by MAO, which produces DOPAC and ROS, 
could be involved in the effects of DA in AtT20 cells. To prevent DA oxidative 
metabolism, AtT20 cells were co-incubated with L-Dopa (1µM) and the MAO inhibitor 
pargyline (10µM). The inhibition of MAO activity prevented the increase in apoptosis 
and the reduction in proliferation rates induced by L-Dopa (Fig. 8A, B). These results 
indicate that the proapoptotic and antiproliferative actions of DA produced from L-




In this study we demonstrated that anterior pituitary cells synthesize DA from L-Dopa 
and this DA can act in an autocrine or paracrine fashion to inhibit PRL secretion. In 
addition, in corticotroph-like cells, we observed effects produced not only by DA 
derived from L-Dopa but also by L-Dopa per se, suggesting that this precursor can 
affect anterior pituitary physiology in a direct manner. 
The synthesis of DA by the anterior pituitary has been extensively discussed (13, 14). 
However, it was observed that this gland did not express a functional TH under 
physiological conditions (11, 20). Few works suggested the presence of AADC in the 
pituitary gland through indirect evidence. For example, the expression of TH in the 
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PRL levels elicited by chronic estradiol treatment. These effects were attributed to DA 
produced in this gland, suggesting the presence of functional AADC (19). 
Herein, we provide direct evidence of AADC immunoreactivity in the anterior pituitary 
gland. Since the anterior lobe is mainly integrated by hormone-producing cells, we 
detected AADC in these cell types including corticotrophs and lactotrophs. Although it 
has been suggested that the anterior pituitary cannot decarboxylate L-Dopa to DA (18), 
we demonstrated in vitro that the anterior lobe could synthesize DA in the presence of 
L-Dopa. Furthermore, we detected the oxidative metabolite DOPAC which is increased 
with the addition of L-Dopa. These results agree with previous assays reporting MAO 
activity in the anterior pituitary (15, 38). 
The potential regulatory role of L-Dopa in the anterior pituitary might implicate the 
secretion of endogenous DA from this lobe. We showed the expression of VMAT2 in 
the anterior pituitary, suggesting that this lobe could store and eventually secrete the 
locally produced DA. In fact, we detected an increase in DA released to the incubation 
media from tissues previously incubated in the presence of L-Dopa.  
To further support our findings of AADC activity, we studied the inhibitory effect of 
DA on the secretion of PRL in vitro. Prolactin levels were measured in conditioned 
media from anterior pituitaries incubated in the presence or absence of L-Dopa. 
Treatment with L-Dopa is known to suppress PRL circulating levels in laboratory 
animals (39-43) and in Parkinson’s (44, 45) or non-parkinsonian patients (46, 47). 
These in vivo effects could be produce at hypothalamic and/or anterior pituitary levels. 
In our study we observed that L-Dopa decreased in vitro PRL release from incubated 
anterior pituitaries, suggesting that these reported effects are mediated, at least partially, 
by anterior pituitary-synthesized DA. Our findings, together with early reports showing 
AADC activity in the anterior pituitary (15, 48), indicate that this lobe can produce 
autocrine/paracrine signals which may involve DA suggesting a potential role of L-
Dopa metabolism in the physiology of this gland. 
In the mediobasal hypothalamus, which includes the median eminence, the presence of 
monoenzimatic neurons expressing TH or AADC has been demonstrated (49) 
suggesting that L-Dopa can be released from TH expressing neurons to AADC 
expressing ones for DA synthesis. Moreover, it has been proposed that L-Dopa can be 
released by TH expressing neurons to the portal vessels reaching the anterior pituitary 
gland (10). In fact, Telford et al. have shown that the concentration of L-Dopa is higher 
in portal blood than in peripheral circulation. The authors conclude that the major 
source of L-Dopa in the anterior pituitary is the portal blood supply because L-Dopa 
was not detected in this lobe when the portal circulation was interrupted by separating 
the pituitary stalk (12). Based on reported concentrations in portal blood of DA (6 ng/ml 
in diestrus rats; (11)) and L-Dopa (40 ng/ml in female rats treated with NSD 1015; 
(12)), we could assume that the greatest contribution of DA would be from an 
endogenous (anterior pituitary) source. However, the concentration of L-Dopa in the 
portal circulation was measured in rats treated with NSD 1015 (an AADC inhibitor), 
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There are other tissues that produce DA from L-Dopa. For example, kidney proximal 
tubules synthesize DA from circulating L-Dopa, which is then converted to DA by 
AADC (50). In summary, we demonstrated for the first time that DA is synthesized 
from L-Dopa in the anterior pituitary gland and that this locally produced DA inhibits 
anterior pituitary PRL secretion. 
Given the small number of corticotrophs in the anterior pituitary gland, we used the 
AtT20 cell line to achieve part of our goals. This tumor-derived cell line allowed us to 
study the direct actions of L-Dopa on ACTH secretion and cell turnover as a first 
experimental approach. Nonetheless, some caution should be taken when interpreting 
the results obtained. 
Horellou et al. suggested the presence of AADC in AtT20 cells since they detected 
intracellular and secreted DA after transducing cells with TH cDNA (51). In line with 
this, we showed that AtT20 cells expressed AADC and VMAT2, and the intracellular 
content of DA increased after incubation with L-Dopa. In addition, AADC blockade 
made DA levels undetectable, indicating that the enzyme is responsible for the 
production of this catecholamine. We hypothesized oxidative deamination might 
represent one of the mechanisms for DA inactivation within corticotrophs. To explore 
this, we studied the production of DOPAC by MAO in AtT20 cells. The accumulation 
of DOPAC increased in an L-Dopa concentration-dependent manner, and the inhibition 
of MAO with pargyline abolished DOPAC synthesis. 
Most in vitro studies investigated the effects of high concentrations of L-Dopa (50 µM-
1 mM) for extended periods (from 12 h to several days) (52). In our study, the 
concentrations of L-Dopa tested in the experiments were 1 and 10 µM. These selected 
concentrations are comparable to the levels found in the plasma of portal vessels (12). 
To elucidate whether L-Dopa treatment alters the secretion of ACTH, we examined the 
effects of locally produced DA and AADC inhibition on basal and CRH-stimulated 
secretion of ACTH. Inhibition of AADC by NSD-1015 in AtT20 cells showed that L-
Dopa decreased ACTH secretion under stimulated conditions. To the best of our 
knowledge, we provide the first evidence showing direct effects of L-Dopa on the 
secretory function of AtT20 cells. In contrast to other reports demonstrating a D2R-
dependent dopaminergic inhibition of ACTH secretion (53), we did not observe such 
effect of local DA in either condition, perhaps due to the lack of D2R expression in 
AtT20 cells (30). The reduction in CRH-stimulated ACTH release in the presence of 
AADC inhibitor suggests that L-Dopa per se interferes with this stimulatory signal. 
These data are consistent with L-Dopa potential role as a neurotransmitter or 
neuromodulator (54). According to Misu et al., the existence of neurons that contain L-
Dopa as an end-product and the fact that other by-products of its metabolism do not 
mimic L-Dopa responses in the presence of AADC inhibition, suggest that this 
precursor fits the criteria to be accepted as an extracellular messenger (54). In fact, L-
Dopa was reported to have binding activity for the gene product of ocular albinism 1 
(OA1), GPR143, a G protein-coupled receptor (GPCR). Moreover, L-Dopa induced 
intracellular Ca2 + response in cell lines that express GPR143 (55). While GPR143 is 
expressed in the central and peripheral nervous system, its expression in the anterior 
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Although the conclusions that can be drawn from the experiments carried out with cell 
lines are limited, our results suggest that corticotrophs could exert a paracrine function 
producing DA and contributing in this way to the inhibition of PRL secretion.  
The role of L-Dopa in apoptosis and survival of dopaminergic neurons has been widely 
studied (55-61), but such effects remain unexplored in corticotrophs. Based on this 
premise, we investigated the effect of L-Dopa in apoptosis and proliferation of AtT20 
cells. In agreement with early reports describing the suppression of lymphocyte 
proliferation by L-Dopa (62, 63), we observed that this precursor, when converted to 
DA, is apoptotic and anti-proliferative in AtT20 cells. On the contrary, when AADC 
was inhibited, L-Dopa acted as an anti-apoptotic and proliferative factor, as described 
for other cell types (64, 65). Our findings provide evidence that the cytotoxicity of L-
Dopa can be attributed, at least in part, to the formation of DA within the cells. On the 
other hand, AADC inhibition unmasked a protective role of L-Dopa in the renewal of 
corticotrophs. This last result highlights this agent would exert direct effects on cell 
viability without the requirement of its metabolism by AADC (52, 66, 67). Even though 
we observed that L-Dopa per se decreases short-term ACTH secretion, we cannot rule 
out that chronic administration may induce other effects on ACTH release, due to the 
proliferative actions of L-Dopa in corticotrophs. More studies are required to clarify this 
point.  
Further experiments were conducted to examine the mechanism by which DA 
synthesized from L-Dopa may be cytotoxic to AtT20 cells. Since our cells do not 
express D2R, we hypothesized that DA might be triggering its apoptotic and anti-
proliferative effects by D2R-independent mechanisms (68, 69). It is known that DA can 
oxidatively damage cells through its metabolism by MAO (36). As we observed 
DOPAC production within AtT20 cells, the actions of the oxidative metabolism of 
endogenous DA on cell turnover were evaluated. Dopamine apoptotic and anti-
proliferative actions were not observed when MAO was inhibited, indicating that the 
activity of this enzyme is essential to observe DA effects on apoptosis and proliferation 
of corticotroph cells.  
In conclusion, L-Dopa is metabolized by AADC to form DA and oxidized by MAO to 
produce DOPAC in the anterior pituitary. Also, this local DA is released as a paracrine 
messenger modulating the secretion of PRL. On the other hand, L-Dopa per se alters the 
secretion of ACTH from AtT20 cells by modifying the action of CRH. Additionally, it 
decreases apoptosis and increases proliferation rates in this cell line. In addition to its 
potential physiological role, L-Dopa treatment is the gold standard for Parkinson´s 
disease treatment (70). In view of our results, it is relevant to study the functions of the 
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Figure Legends 
Figure 1. AADC is expressed in corticotrophs, lactotrophs, somatotrophs and 
gonadotrophs. (A) AADC expression in the anterior pituitary was detected by western 
blot (AP, anterior pituitary; STR, striatum). (B) Primary cultures of anterior pituitary 
cells from adult male rats were processed for identification of AADC and pituitary 
hormones by double immunofluorescence. Representative microphotographs show the 
expression of AADC (green) in PRL, GH, ACTH, and LH positive cells (red). Nuclei 
were stained with DAPI (blue). Scale bars: 20 µm.  
 
Figure 2. VMAT2 is expressed in corticotrophs, lactotrophs, somatotrophs and 
gonadotrophs. (A) VMAT2 expression in the anterior pituitary was detected by western 
blot (AP, anterior pituitary; STR, striatum). (B) Primary cultures of anterior pituitary 
cells from adult male rats were processed for identification of VMAT2 and pituitary 
hormones by double immunofluorescence. Representative microphotographs show the 
expression of VMAT2 (green) in PRL, GH, ACTH, and LH positive cells (red). Nuclei 
were stained with DAPI (blue). Scale bars: 20 µm. 
 
Figure 3. L-Dopa is metabolized in the anterior pituitary gland and plays a potential role 
in PRL secretion. Each column represents the mean ± SEM. (A and B) DA and DOPAC 
tissue levels (n=7/group) were detected by HPLC in anterior pituitary fragments. In the 
presence of L-Dopa (10 µM) the content of DA and DOPAC was increased.*p<0.05 
(t=2.466 df=11), **p<0.01 (t=3.600 df=11), unpaired t-test. (C) DA was detected by 
HPLC in conditioned media (n=6 wells/group) from anterior pituitary fragments 
incubated with or without L-Dopa. In the presence of L-Dopa (10 µM) the content of 
was increased. **p<0.01 (t=4.029; df=10), unpaired t-test (D) PRL content was detected 
by ELISA in conditioned media (n=14 wells/group) from anterior pituitary fragments 
incubated with or without L-Dopa (10 μM). **p<0.01 (t=3.875 df=25), unpaired t-test. 
 
Figure 4. AADC and VMAT2 are expressed in anterior pituitary cell lines. GH3 and 
AtT20 cells were processed for the identification of AADC (A) or VMAT2 (B) by 
immunofluorescence. Microphotographs show AADC or VMAT2 (green) expression. 
Nuclei were stained with DAPI (blue). The PC12 cell line was used as a positive 
control.  Results were confirmed by western blot of proteins from GH3, AtT20 and 
PC12 cells. Scale bars: 20 µm. 
 
Figure 5. DA and DOPAC are produced from exogenous L-Dopa in AtT20 cells. Each 
column represents the mean ± SEM (n=4/group). DA (A) and DOPAC (B) were 
detected in AtT20 cells by HPLC after incubation with 1 or 10 µM L-Dopa. DA and 
DOPAC were not detectable (ND) in the presence of NSD-1015. **p<0.01 vs. 0 µM L-
Dopa, one-way ANOVA (A:. F(4,15) = 215.9; B: F(4,15) = 76.19) followed by Tukey’s 
test (C) MAO inhibitor (pargyline, 10µM) prevents the production of DOPAC and 
increases the content of DA measured by HPLC. **p<0.01 vs. 10µM L-Dopa without 
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Figure 6. L-Dopa plus an AADC inhibitor reduces CRH-stimulated ACTH secretion 
from AtT20 cells. Each column represents the mean ± SEM (n=9 wells/group) of 
ACTH levels (ng/ml). ACTH was measured in culture media from AtT20 cells by 
enzyme immunoassay (EIA) both in basal (A) and under CRH (100 nM) stimulated 
conditions (B). *p<0.05 vs. respective controls without L-Dopa, ^p<0.05 vs. respective 
control without NSD 1015, two-way ANOVA (A: L-Dopa: F (1, 32) = 1.339, p>0.05; 
NSD 1015: F (1, 32) = 0.005811; p> 0.05; Interaction: F (1, 32) = 1.276, p>0.05). B: L-
Dopa: F(1,31) = 4.749, p<0.05; NSD 1015: F(1,31) = 0.8971, p>0.05; Interaction:  
F(1,31) = 6.789, p<0.05) followed by Newman-Keuls’ multiple comparisons test.  
 
Figure 7. AADC inhibition reverses apoptotic and antiproliferative effects induced by 
L-Dopa. Each column represents the percentage ± confidence limit (CL: 95%) of 
apoptotic (A) or proliferative (B) AtT20 cells (n≥1000 cells/group) determined by 
TUNEL or BrdU incorporation assays, respectively. **p<0.01 vs. respective controls 
without L-Dopa, ^^p<0.01 vs respective control without NSD-1015, χ2 test. Lower 
panels show representative microphotographs of TUNEL+ or BrdU+ cells (green). 
Nuclei were stained with DAPI (blue). Arrowheads indicate the location of TUNEL or 
BrdU positive nuclei. Scale bars: 50 µm. 
 
Figure 8. MAO inhibition reverses apoptotic and antiproliferative effects induced by L-
Dopa converted to DA. Each column represents the percentage ± confidence limit (CL: 
95%) of apoptotic (A) or proliferative (B) AtT20 cells (n≥1000 cells/group) determined 
by TUNEL or BrdU incorporation assays, respectively. **p<0.01 vs. respective control 














Figure 1. AADC is expressed in corticotrophs, lactotrophs, somatotrophs and 
gonadotrophs. (A) AADC expression in the anterior pituitary was detected by western 
blot (AP, anterior pituitary; STR, striatum). (B) Primary cultures of anterior pituitary 
cells from adult male rats were processed for identification of AADC and pituitary 
hormones by double immunofluorescence. Representative microphotographs show the 
expression of AADC (green) in PRL, GH, ACTH, and LH positive cells (red). Nuclei 

























Figure 2. VMAT2 is expressed in corticotrophs, lactotrophs, somatotrophs and 
gonadotrophs. (A) VMAT2 expression in the anterior pituitary was detected by western 
blot (AP, anterior pituitary; STR, striatum). (B) Primary cultures of anterior pituitary 
cells from adult male rats were processed for identification of VMAT2 and pituitary 
hormones by double immunofluorescence. Representative microphotographs show the 
expression of VMAT2 (green) in PRL, GH, ACTH, and LH positive cells (red). Nuclei 














Figure 3. L-Dopa is metabolized in the anterior pituitary gland and plays a potential role 
in PRL secretion. Each column represents the mean ± SEM. (A and B) DA and DOPAC 
tissue levels (n=7/group) were detected by HPLC in anterior pituitary fragments. In the 
presence of L-Dopa (10 µM) the content of DA and DOPAC was increased.*p<0.05 
(t=2.466 df=11), **p<0.01 (t=3.600 df=11), unpaired t-test. (C) DA was detected by 
HPLC in conditioned media (n=6 wells/group) from anterior pituitary fragments 
incubated with or without L-Dopa. In the presence of L-Dopa (10 µM) the content of 
was increased. **p<0.01 (t=4.029; df=10), unpaired t-test (D) PRL content was detected 
by ELISA in conditioned media (n=14 wells/group) from anterior pituitary fragments 

































Figure 4. AADC and VMAT2 are expressed in anterior pituitary cell lines. GH3 and 
AtT20 cells were processed for identification of AADC (A) or VMAT2 (B) by 
immunofluorescence. Microphotographs show AADC or VMAT2 (green) expression. 
Nuclei were stained with DAPI (blue). The PC12 cell line was used as a positive 
control.  Results were confirmed by western blot of proteins from GH3, AtT20 and 














Figure 5. DA and DOPAC are produced from exogenous L-Dopa in AtT20 cells. Each 
column represents the mean ± SEM (n=4/group). DA (A) and DOPAC (B) were 
detected in AtT20 cells by HPLC after incubation with 1 or 10 µM L-Dopa. DA and 
DOPAC were not detectable (ND) in the presence of NSD-1015. **p<0.01 vs. 0 µM L-
Dopa, one-way ANOVA (A:. F(4,15) = 215.9; B: F(4,15) = 76.19) followed by Tukey’s 
test (C) MAO inhibitor (pargyline, 10µM) prevents the production of DOPAC and 
increases the content of DA measured by HPLC. **p<0.01 vs. 10µM L-Dopa without 























Figure 6. L-Dopa plus an AADC inhibitor reduces CRH-stimulated ACTH secretion 
from AtT20 cells. Each column represents the mean ± SEM (n=9/group) of ACTH 
levels (ng/ml). ACTH was measured in culture media from AtT20 cells by enzyme 
immunoassay (EIA) both in basal (A) and under CRH (100 nM) stimulated conditions 
(B). *p<0.05 vs. respective controls without L-Dopa, ^p<0.05 vs. respective control 
without NSD 1015, two-way ANOVA (A: L-Dopa: F (1, 32) = 1.339, p>0.05; NSD 
1015: F (1, 32) = 0.005811; p> 0.05; Interaction: F (1, 32) = 1.276, p>0.05). B: L-Dopa: 
F(1,31) = 4.749, p<0.05; NSD 1015: F(1,31) = 0.8971, p>0.05; Interaction:  F(1,31) = 
























Figure 7. AADC inhibition reverses apoptotic and antiproliferative effects induced by 
L-Dopa. Each column represents the percentage ± confidence limit (CL: 95%) of 
apoptotic (A) or proliferative (B) AtT20 cells (n≥1000 cell/group) determined by 
TUNEL or BrdU incorporation assays, respectively. **p<0.01 vs. respective controls 
without L-Dopa, ^^p<0.01 vs respective control without NSD-1015, χ2 test. Lower 
panels show representative microphotographs of TUNEL+ or BrdU+ cells (green). 
Nuclei were stained with DAPI (blue). Arrowheads indicate the location of TUNEL or 




















Figure 8. MAO inhibition reverses apoptotic and antiproliferative effects induced by L-
Dopa converted to DA. Each column represents the percentage ± confidence limit (CL: 
95%) of apoptotic (A) or proliferative (B) AtT20 cells (n≥1000 cell/group) determined 
by TUNEL or BrdU incorporation assays, respectively. **p<0.01 vs. respective control 
without L-Dopa, ^^p<0.01 vs. respective control without pargyline, χ2 test. 
 
 
 
 
 
 
 
